Dr Danilo Fliser, Germany speaking about ‘Once monthly C.E.R.A. provides stable Hb levels within narrow target ranges following direct switch from shorter acting ESA - The MIRACEL study’ Poster number 559, WCN 2009, Milan (Poster number M558)
“It was very easy to switch patients regardless from which treatment regimen before, regardless of whether IV or SC administered, regardless of the frequency of administration to Mircera”
